LifeScan Teams Up with Sanvita Medical to Launch a Continuous Glucose Monitor (CGM) System


Register to receive a free U.S. Market Report Suite for Diabetes Devices report synopsis and brochure

On May 21 2019, LifeScan announced a partnership with Sanvita Medical to move into the continuous glucose monitoring (CGM) market this week, which is poised to become the standard of care for the vast majority of people with diabetes who do not use insulin.

This partnership moves LifeScan into a fast-growing field, potentially helping it to offset the market pressures. However, LifeScan will see competition for the market, which is fought over by leading, well-established companies like Novo Nordisk and Eli Lilly, according to U.S. Market Report Suite for Diabetes Devices report from  iData Research.

Sanvita Medical is designing a CGM sensor that combines with LifeScan’s OneTouch Reveal digital portfolio, including the OneTouch Reveal smartphone app, which was developed when LifeScan was owned by Johnson & Johnson. The app collects data from OneTouch meters, which allows patients insights on blood glucose trends, and can share this data with a physician or a clinician. The OneTouch brand of blood glucose meters, testing strips, lancets, and point-of-care systems are very well known to individual consumers and hospitals.

“Soon we will be able to offer the spectrum of diabetes monitoring solutions—from our blood glucose monitoring systems to our digital products to CGM technologies with Sanvita,” Asbury says.

According to research from iData Research, in the 2018 U.S. market, the personal continuous glucose monitoring market accounted for the vast majority of the total market value. Personal CGM is used by individuals on a day-to-day basis and has experienced significant growth in recent years, due to an expanding installed base and advancements in device technology. Growth is expected to continue over the forecast period and will be driven by favorable reimbursement, technological innovation and an increased uptake of personal CGM among type 1 diabetics and insulin-dependent type 2 diabetics.

“Through this agreement, LifeScan will soon be able to offer the spectrum of diabetes monitoring solutions to meet almost any need for a wide variety of patients (type 1 and type 2)—from our blood glucose monitoring products to our digital products to CGM products with Sanvita,” Bridget Doherty, spokesperson of LifeScan said.



More on the diabetes device market in the U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Diabetes Devices . The suite covers reports on the following markets: blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, insulin pens, insulin syringes and insulin pumps.

The iData report series on diabetes devices covers the US and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about diabetes device market data or procedure data, register online or email us at for a Europe Market Report Suite for Diabetes Devices brochure and synopsis.

Leave a Reply